

QIBA – EARL Collaboration

In August 2020, [QIBA](#) – the Quantitative Imaging Biomarker Alliance of the [Radiological Society of North America](#) and [EARL](#) – an initiative of the [European Association of Nuclear Medicine](#), signed a Memorandum of Understanding to collaborate on PET/CT scanner harmonization and the wider application of PET/CT quantification in nuclear medicine imaging in clinical trials and clinical practice.

A year later, nine clinical sites across Europe and Japan – all EARL-accredited for FDG-PET/CT imaging – successfully passed the conformance test for the QIBA FDG-PET/CT Profile. This means such centers are not only conducting best-practice FDG-PET/CT imaging, but also provide high-quality quantitative imaging to their patients. The uptake of the radiopharmaceutical can be measured reliably and reproducibly at these centers of excellence. This could help many cancer patients and those with COVID-19 or Long COVID.

The QIBA and EARL collaboration continues to advance quantitative imaging harmonization applied internationally.

Soon more EARL-accredited sites will be achieving the level of imaging excellence. This collaboration will expand to additional radiopharmaceuticals beyond [¹⁸F]F-FDG.